Depression, Unipolar Clinical Trial
— LIVESOfficial title:
LIVES: Development of/a Personalized Lifestyle Intervention for Patients With Depression in Psychiatric Outpatient Care and General Practice in a Pilot Study
Persons with affective disorder have a considerably increased risk of cardiovascular disease. To a considerable extent, this is due to an unhealthy life style. At present, no adequate lifestyle interventions are available for these patients. In the present pilot intervention study we study the acceptability and feasibility of a newly developed lifestyle intervention that is specifically tailored to the needs of patients with affective disorders treated in mental health care or general practice.
Status | Recruiting |
Enrollment | 38 |
Est. completion date | December 1, 2025 |
Est. primary completion date | December 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: For patients in mental health care only: - Outpatients - Diagnosed during intake, the primary diagnosis being chronic bipolar disorder (type I or 2) or a chronic or recurrent severe depression in the narrower sense of the word - Receiving psychopharmacological treatment - Have had a physical and lifestyle Routine Outcome Monitoring measurement showing that three or more metabolic parameters were outside the normal range For patients in general practice (GP) only: - Diagnosis of depressive symptoms or depressive disorder in the past year as registered in the general practice electronic health record and coded according to the International Classification of Primary Care (ICPC) as P03 and P76, respectively, - At least mild depressive symptom level according to the Beck Depression Inventory-II (BDI) (score =14) - Body mass index = 25 kg/m2 or increased waist circumference (>88cm (women) of >102cm (men)). For both patient groups: - 18 years or older and capable to participate in the intervention according to the treating physician Availability of one or two people close to the patient (friends or family, preferably sharing the same household), i.e. to act as the buddy of the patient. Exclusion Criteria: - For GP patients only: current treatment in mental health care (GGZ in Dutch) - For GP patients only: severe somatic / neurological disease at the discretion of the GP - Currently participating in another lifestyle intervention - Insufficient proficiency in Dutch - Unability to read and write |
Country | Name | City | State |
---|---|---|---|
Netherlands | GGZ Drenthe | Assen | Drenthe |
Netherlands | University Medical Center Groningen | Groningen |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen | GGZ Drenthe Mental Health Institution |
Netherlands,
Knol MJ, Heerdink ER, Egberts AC, Geerlings MI, Gorter KJ, Numans ME, Grobbee DE, Klungel OH, Burger H. Depressive symptoms in subjects with diagnosed and undiagnosed type 2 diabetes. Psychosom Med. 2007 May;69(4):300-5. doi: 10.1097/PSY.0b013e31805f48b9. Epub 2007 Apr 30. — View Citation
Ormel J, Von Korff M, Burger H, Scott K, Demyttenaere K, Huang YQ, Posada-Villa J, Pierre Lepine J, Angermeyer MC, Levinson D, de Girolamo G, Kawakami N, Karam E, Medina-Mora ME, Gureje O, Williams D, Haro JM, Bromet EJ, Alonso J, Kessler R. Mental disorders among persons with heart disease - results from World Mental Health surveys. Gen Hosp Psychiatry. 2007 Jul-Aug;29(4):325-34. doi: 10.1016/j.genhosppsych.2007.03.009. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reach of LIVE | Reach of our intervention as defined by the absolute number, proportion, and representativeness of individuals who are willing to participate in LIVE | 27 months (September 2020 through November 2022) | |
Primary | Adherence to LIVE | Adherence to the LIVE lifestyle intervention as defined by the number of sessions attended by the participant out of the total of 18 sessions | 18 weeks | |
Primary | Drop out from LIVE | Drop-out from the LIVE intervention as defined by the proportion of participants who decide to prematurely stop taking part in the LIVE intervention | 18 weeks | |
Primary | Feasibility and acceptability of the LIVE intervention according to the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability of the LIVE intervention will be assessed using qualitative interviews Participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 3 | |
Primary | Feasibility and acceptability of the LIVE intervention according to the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability of the LIVE intervention will be assessed using qualitative interviews Participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 6 | |
Primary | Feasibility and acceptability of the LIVE intervention according to the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability of the LIVE intervention will be assessed using qualitative interviews Participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 9 | |
Primary | Feasibility and acceptability of the LIVE intervention according to the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability of the LIVE intervention will be assessed using qualitative interviews Participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 12 | |
Primary | Feasibility and acceptability of the LIVE intervention according to the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability of the LIVE intervention will be assessed using qualitative interviews Participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 15 | |
Primary | Feasibility and acceptability of the LIVE intervention according to the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability of the LIVE intervention will be assessed using qualitative interviews Participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 18 | |
Secondary | Feasibility and acceptability of the LIVE intervention according to the buddy of the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability will be assessed using qualitative interviews. Buddies of participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 3 | |
Secondary | Feasibility and acceptability of the LIVE intervention according to the buddy of the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability will be assessed using qualitative interviews. Buddies of participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 6 | |
Secondary | Feasibility and acceptability of the LIVE intervention according to the buddy of the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability will be assessed using qualitative interviews. Buddies of participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 9 | |
Secondary | Feasibility and acceptability of the LIVE intervention according to the buddy of the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability will be assessed using qualitative interviews. Buddies of participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 12 | |
Secondary | Feasibility and acceptability of the LIVE intervention according to the buddy of the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability will be assessed using qualitative interviews. Buddies of participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 15 | |
Secondary | Feasibility and acceptability of the LIVE intervention according to the buddy of the participant as assessed by qualitative interviews and qualitative data analysis | Feasibility and acceptability will be assessed using qualitative interviews. Buddies of participants will be interrogated on how they experienced themes during the different modules of the intervention. A topic-list will be used by the interviewer to check whether all relevant themes on feasibility and acceptability have been discussed | Up to week 18 | |
Secondary | Quality of life as assessed by The Manchester Short Assessment of Quality of Life (MANSA). | The MANSA measures quality of life focusing on satisfaction with life as a whole and with life domains and consists of a 12-item self-report questionnaire | Baseline, at the end of the intervention 18 weeks after baseline, and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Depressive symptoms according to the Beck Depression Inventory-II (BDI-II) | The BDI-II is a self-report (21 items) rating inventory which measures depressive symptom level | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Recovery of the participant according to the Individual Recovery Outcomes Counter (I.ROC) | The I.ROC is an instrument to quantitatively measure recovery. It uses three indicators on four areas of wellbeing, namely home, opportunity, people, empowerment. | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Wellbeing as assessed by the Mental Health Continuum Short Form (MHC-SF) | The MHC-SF measures emotional, social and psychological wellbeing and is a self-report with 14 items | Baseline, halfway and at the end of the intervention 18 weeks after the intervention, and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) | The PSQI is a self-report questionnaire that assesses sleep quality over a one-month interval and consists of 19 individual items. | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Alcohol consumption and alcohol-related problems according to the Alcohol Use Disorders Identification test (AUDIT) | The AUDIT consists of 10 items scoring both consumption and alcohol-related problems. We will use the total scale on consumption and problem drinking | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Treatment success according to the Outcome Questionnaire-45 | a questionnaire to measure treatment success. It has three subscales: 1. Symptomatic distress (25 items, including symptoms of depression, anxiety and drug dependency, 2. Interpersonal relations (11 items) en 3. Social Role (9 items) . | The questionnaire will be administered after every five modules of the intervention. | |
Secondary | Dietary intake of the participant according to a self devised questionnaire | The questionnaire is a nutrition list with 25 items to measure the dietary intake of patients | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Activity level defined as the daily number of steps | The daily number of steps will be measured using the Fitbit Zip as described by Naslund et al., 2016 | From baseline up to the 6 months follow up (42 weeks after baseline) | |
Secondary | Body height of the participant as assessed by a stadiometer | Body height in meters | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Body weight of the participant as assessed by a medical weight scale | Body weight in kilograms | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Waist circumference of the participant as assessed using a tape meter line | Waist circumference in centimeters | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05114824 -
Acceptability and Feasibility of an 8-week Online Mindfulness-Based Cognitive Therapy Program Among Undergraduate Students
|
N/A | |
Not yet recruiting |
NCT05958940 -
BioClock: Bright Light Therapy for Depressive Disorders
|
N/A | |
Completed |
NCT03556735 -
Pulsed Electro Magnetic Fields (PEMF) in Depression
|
N/A | |
Completed |
NCT04916548 -
Repeated Neurocognitive Measurements in Depressed Patients
|
Phase 1/Phase 2 | |
Completed |
NCT06094907 -
Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression
|
Phase 2 | |
Completed |
NCT04121091 -
Pramipexole to Target "Anhedonic Depression"
|
Phase 2 | |
Recruiting |
NCT06092411 -
Effects of CBT and BLT in Youth With Unipolar Depression and Evening Chronotype
|
N/A | |
Enrolling by invitation |
NCT03847688 -
Machine Learning to Predict Clinical Response to TMS
|
||
Completed |
NCT02945735 -
Gaze Contingent Feedback in Major Depressive Disorder (MDD)
|
N/A | |
Recruiting |
NCT06139159 -
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
|
N/A | |
Recruiting |
NCT05011864 -
Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression
|
N/A | |
Terminated |
NCT03537547 -
Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder
|
Phase 4 | |
Completed |
NCT03515733 -
PF-04995274 and Emotional Processing in Treatment Resistant Depression
|
Phase 1 | |
Not yet recruiting |
NCT05991232 -
Repeated Neurocognitive Measurements in Depressed Patients
|
Phase 1/Phase 2 | |
Completed |
NCT03516604 -
PF-04995274 and Emotional Processing in Un-medicated Depression
|
Phase 1 | |
Completed |
NCT03538275 -
Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
|
||
Active, not recruiting |
NCT03096886 -
Novel Neural Circuit Biomarkers of Major Depression Response to CCBT
|
N/A | |
Not yet recruiting |
NCT06462196 -
Natural History of Depression, Bipolar Disorder and Suicide Risk
|
||
Completed |
NCT01874951 -
Low-Dose Naltrexone for Depression Relapse and Recurrence
|
Phase 2 | |
Completed |
NCT03906175 -
Whole-body Hyperthermia for Mild to Moderate Depressive Disorder
|
N/A |